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Abstract
Contrast-enhanced ultrasound (CEUS) greatly improved the diagnostic accuracy of US in the detection and
characterization of focal liver lesions (FLLs), and it is suggested and often included in many international guidelines
as an important diagnostic tool in the imaging work-up of cirrhotic patients at risk for developing hepatocellular
carcinoma (HCC). In particular, CEUS Liver Imaging Reporting and Data System (LI-RADS) provides standardized
terminology, interpretation, and reporting for the diagnosis of HCC. The aim of this pictorial essay is to illustrate
CEUS features of nodules discovered at US in cirrhotic liver according to LI-RADS categorization.
Keywords: Contrast-enhanced ultrasonography, Hepatocellular carcinoma, Cholangiocarcinoma, Liver tumor
characterization, Cirrhosis
Key points
 CEUS is a safe, robust, and cost-effective imaging
modality
 CEUS allows in real time a confident
characterization of hepatocellular carcinoma (HCC)
 CEUS LI-RADS provides standardized terminology,
interpretation, and reporting for the diagnosis of
HCC
Introduction
Worldwide HCC is reported to be the sixth most com-
mon tumor and the fourth cause of death related to can-
cer [1].
Cirrhotic patients are particularly considered a high-
risk group for the onset of HCC, prompting several
international scientific societies to publish guidelines
recommending surveillance of adults with cirrhosis on
the evidence of improved overall survival [2–4]. The rec-
ommended imaging surveillance tool for early detection
of HCC is ultrasound (US), usually performed every
6 months [2, 3]. Once a new nodule suspect for HCC is
discovered in the liver of a cirrhotic patient, further im-
aging work-up with either computed tomography (CT)
or magnetic resonance imaging (MRI) is usually recom-
mended [2, 3]. Both techniques require the intravenous
administration of contrast media and difficulties may
arise in patients with severe renal failure or allergies [5,
6].
Contrast-enhanced US (CEUS) allows to assess non-
invasively the contrast enhancement patterns of HCC,
without the use of ionizing radiation and with a much
higher temporal resolution than CT and MRI [7–10].
This unique feature of CEUS virtually eliminates the
possibility of image acquisition mistiming, especially in
the arterial phase [11]. Several studies have reported the
improvement in diagnostic accuracy of CEUS in the de-
tection and characterization of FLLs, including HCC [8–
11]. CEUS has been also proved useful in the guidance
and response assessment of therapeutic procedures [12–
18].
CEUS examination is performed by injecting intraven-
ously microbubble-based contrast agents (USCAs) con-
sisting of flexible shells (e.g., phospholipids, liposomes)
presenting a radius ranging from 1 to 10 μm, containing
low solubility gases (e.g., perfluoropropane, perfluoro-
carbon, or sulphur hexafluoride) [19, 20]. USCAs micro-
bubbles pass through the lung capillary bed and they
remain confined within the intravascular space. Al-
though some USCAs may present a post-vascular phase
in the liver and spleen, this phase is currently not taken
in account for the characterization of HCC [21]. Ap-
proximately 20 min after the injection, the USCAs are
completely eliminated: the gas diffuses into the blood
and then exhaled via the pulmonary route, while the
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Table 1 Main indications for CEUS LI-RADS in patients at high risk for HCC
Assess nodules ≥ 10 mm detected on surveillance US.
Assess LR-3, LR-4, and LR-M observations detected on prior CT or MRI.
Detect APHE when mistiming is suspected as the reason for its absence on prior CT or MRI.
Assess biopsied observations with inconclusive histology.
Guide biopsy or treatment of observations difficult to visualize with precontrast US.
Help select appropriate observation(s) or observation component(s) for biopsy.
Monitor changes in enhancement pattern over time for selected CEUS LR-3 or CEUS LR-4 observations.
Differentiate tumor in vein (“tumor thrombus”) from bland thrombus.
Fig. 1 ACR CEUS LI-RADS categorization and diagnostic algorithm
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shell components are metabolized by the liver or filtered
by the kidney [22].
USCAs are generally safe and well tolerated with a
safety profile better than or similar to CT and MRI con-
trast media [23]. They are not nephrotoxic and may be
used even in patients with severe renal failure, renal ob-
struction, or chronic obstructive pulmonary disease.
Hence, there is no need of laboratory tests for assessing
renal function before administering USCAs.
Currently, in many clinical settings, CEUS is recom-
mended as pivotal imaging tool in the diagnostic work-
up of liver FLLs, including HCC, also considering its fa-
vorable cost-benefit ratio when compared with cross-
sectional imaging techniques [24–27]. In a recent meta-
analysis, CEUS showed excellent diagnostic accuracy in
differentiating malignant from benign FLLs with pooled
sensitivity of 0.92, pooled specificity of 0.87, and diag-
nostic odds ratio of 104.20 respectively [21].
The CEUS cases presented in this paper were acquired
by means of various ultrasound equipments: RS80A and
RS85, (Samsung Medison, Co. Ltd.), iU22 (Philips Ultra-
sound, Bothell, Wash, USA), and MyLab Twice (Esaote,
Genova, Italy). All of these units were provided with
multifrequency convex array probes and contrast-
specific imaging software.
CEUS LI-RADS
CEUS LI-RADS system
Firstly released in 2016 by the ACR and then revised in
2017, contrast enhanced ultrasound (CEUS) Liver Im-
aging Reporting and Data System (LI-RADS) is a stan-
dardized system for technique, interpretation, reporting,
Table 2 CEUS LI-RADS categories
Diagnostic
categories
Clinical significance Imaging workup options
Return to routine surveillance Alternative diagnostic imaging (i.e., CT or MRI) Repeat CEUS
CEUS LR-NC Not categorizable (due to image degradation or omission) – ≤ 3 months* ≤ 3 months**
CEUS LR-1 Definitely benign 6 months** – –
CEUS LR-2 Probably benign 6 months** – ≤ 6 months*
CEUS LR-3 Intermediate probability of malignancy – ≤ 6 months** ≤ 6 months*
CEUS LR-4 Probably HCC Multidisciplinary discussion may be needed for consensus management. If neither biopsy nor
treatment is planned: repeat or alternative diagnostic imaging in ≤ 3 months
CEUS LR-5 Definitely HCC Diagnosis of HCC. Multidisciplinary discussion for consensus management.
CEUS LR-M Probably or definitely malignant, not necessarily HCC Multidisciplinary discussion for consensus management.
May include alternative or repeat imaging, biopsy, or treatment
CEUS LR-TIV Tumor in vein Multidisciplinary discussion for consensus management. May include biopsy or biomarker
correlation to determine etiology of TIV: HCC, ICC, other.
**Preferred option in most cases
*Reasonable alternative option. Not recommended
Fig. 2 CEUS LI-RADS 1 (definitely benign). Complex cyst in a 60-year-old woman with chronic hepatitis B viral infection. Baseline US image (a)
shows a heterogeneous and moderately hypoechoic lesion sized 6.2 cm in the segment VI–VII (arrows). At CEUS (b), the lesion shows a complete
lack of enhancement throughout the vascular phases (arrows)
Bartolotta et al. Insights into Imaging            (2020) 11:9 Page 3 of 13
and data collection for CEUS exams in patients at risk
for developing HCC [28].
CEUS LI-RADS lexicon integrates with the previously
released CT/MRI LI-RADS lexicons, and it is intended
to allow the radiologists to (1) use consistent termin-
ology, (2) reduce variability and mistakes in imaging in-
terpretation, (3) promote communication with referring
clinicians, and (4) facilitate research and quality assur-
ance [29].
Noteworthy, although FLL characterization features
using CEUS are similar to those of multiphasic CT and/
or MRI, there are still important differences between
these techniques, regarding both features and
characterization algorithm [30]. CEUS LI-RADS is
Fig. 3 CEUS LI-RADS 1 (definitely benign). Hemangioma in a 49-year-old woman with chronic hepatitis B viral infection. Baseline US image (a)
shows a hypoechoic lesion surrounded by a tiny peripheral hyperechoic rim sized 1.3 cm in the segment VII (calipers). CEUS in the early arterial
phase (b) depicts peripheral globular enhancement (arrows) followed by a complete centripetal fill-in in the late arterial phase (c) (arrows). The
lesion shows sustained contrast-enhancement in the extended portal-venous phase (d) (arrows)
Fig. 4 CEUS LI-RADS 2 (probably benign). Atypically located area of hypersteatosis in a 47-year-old woman with chronic hepatitis B viral infection.
Baseline US image (a) shows a hyperechoic oval-shaped area sized 2.8 cm in the segment IV in a fatty liver (arrow). At CEUS in the
extended portal venous phase (b), the area is constantly isoechoic with respect to the surrounding liver parenchyma, as well as throughout the
vascular study (arrow)
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intended for the use with purely intravascular microbub-
ble contrast agents—such as Lumason® (in USA)/Sono-
Vue® (outside USA) and Definity® (in USA, Canada)/
Luminity® (outside USA, Canada)—which affects wash-
out and “capsule” characterization [11, 31, 32]. Actually,
CEUS washout is true washout. On the other hands,
CEUS does not depict “capsule”; hence, “capsule” is not
a CEUS major feature. CEUS usually does not depict
vascular pseudo-lesions such as arterioportal shunts, a
frequent cause of diagnostic confusion on CT and MRI:
as consequence, any CEUS enhancing observation is a
true lesion [33].
Of note, the use of a combined blood pool and Kupffer
cell agent (Sonazoid®) is not contemplated in FLL
characterization using CEUS LI-RADS [28].
When is CEUS LI-RADS categorization system indicated?
CEUS LI-RADS must be applied only in patients at high
risk for developing HCC (cirrhosis, chronic hepatitis B,
current or prior HCC, adult liver transplant candidates,
and recipients after transplant). CEUS LI-RADS must not
be applied to patients without the abovementioned risk
factors or < 18 years old. Table 1 lists the man indications
of CEUS LI-RADS in patients at high risk for HCC [28].
CEUS LI-RADS reporting and categories
According to CEUS LI-RADS criteria, the two major fea-
tures of HCC are (1) arterial phase enhancement (not
rim or globular peripheral) and (2) washout. Not surpris-
ingly, CEUS sensitivity in the observation of arterial
hypervascularity from nodules in liver cirrhosis has been
showed to be significantly higher than that of CT/MRI
[34–36].
Washout
Washout is defined as a reduction in enhancement in
whole or in part in comparison with the liver resulting
in hypoenhancement. This latter may begin during or
after arterial phase. Furthermore, CEUS characterization
of washout requires assessment of its onset (late vs.
early) and degree (mild vs. marked), not just its pres-
ence. Actually, early (< 60 s) and/or marked washout is a
major feature for LR-M [37]. On the other hand, late (≥
60 s) and mild washout is a major feature for HCC [38].
The degree of washout is defined “mild” when the
nodule enhances less than liver, but not some enhance-
ment persists. If this persistent enhancement disappears
after 2 min, the degree of washout is still considered
mild, even if the nodule eventually becomes “punched-
out.” On the other hand, the degree of washout is de-
fined “marked” when the nodule lacks of any contrast
enhancement within 2 min after contrast injection: the
observation appears black or “punched out.”
The ancillary imaging features can be taken into ac-
count for category adjustment when category classifica-
tion is not definite and, as stated by ACR, they can be
Fig. 5 CEUS LI-RADS 2 (probably benign). Regenerative nodule in a 68-year-old woman with virus B-related cirrhosis. Baseline US image (a) shows
a small hypoechoic lesion sized 0.9 cm in the segment III (calipers). At CEUS, the nodule is constantly isoechoic with respect to the surrounding
liver parenchyma during the arterial (a) and extended portal venous phase (b, c)
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used to upgrade or downgrade unclear FLLs categories.
Presence of ancillary features favoring malignancy (size
growth, mosaic, and nodule in nodule architecture) can
only upgrade by one category (except LR-4 to LR-5) un-
clear lesions. On the other hand, presence of ancillary
features favoring benignity (size stability or size reduc-
tion) can only downgrade by one category unclear le-
sions. When conflicting, it is recommended not to use
them to adjust category.
The presence of patent veins or the presence of
thrombosis must be assessed as well [28]. Currently,
there are eight CEUS LI-RADS diagnostic categories
with related imaging work-up suggestions (Fig. 1). In
particular, categories from 1 to 5 include nodules with
increasing probability of malignancy. Of note, a one-to-
one correspondence between such categories and histo-
logic progression or grade of cirrhosis-associated nod-
ules does not exist [39]. As consequence, no cirrhotic
nodule is included in LR-1 and many HCCs might be
categorized LR-4 or lower. The LR categorization impact
on the imaging workup options as well, as described in
Table 2.
How to apply CEUS LI-R-RADS system?
If after the injection of microbubble contrast agent, any
observation results not assessable due to image degrad-
ation or omission, CEUS LR-NC (not categorizable)
must be used. In this case, information about the cause
technical limitations or artifacts should be reported and
further work-up advice should be also provided, such as
repeat CEUS or perform alternative imaging modality
(i.e., CT and/or MRI) within 3months (Table 2).
CEUS LR-1 and 2 categories include definitely and
probably benign observations, respectively: in particular,
LR-1 includes three main observation types: (1) cyst, (2)
hemangioma, (3) fat deposition/sparing. A liver cyst is
defined, as elsewhere in the body, as an anechoic lesion
with increased posterior acoustic through transmission
showing no contrast enhancement in any phase. Al-
though simple cysts are easily detected and characterized
even without the use of any contrast agent, CEUS may
be of particular value in the characterization of more
complex appearing lesions on B-mode US, showing their
complete avascularity (Fig. 2) [8, 15]. Hemangioma is
often recognized as a hyperechoic lesion, but it may
Fig. 6 CEUS LI-RADS 2 (probably benign). Non mass-like area in a 57-year-old man with virus C-related cirrhosis. Baseline US image (a) shows a
slightly hyperechoic area with indistinct margins sized 7 cm in the segment V–VI (arrows). The area does not show any vascular signal at color-
Doppler (b) (arrows). At CEUS (c), it appears constantly isoechoic with respect to the surrounding liver parenchyma throughout the vascular
study (arrows)
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present variable echogenicity on B-mode US [40]. CEUS
easily depicts a typical peripheral globular enhancement
in arterial phase followed by progressive centripetal fill-
in and iso- or hyperenhancement in portal venous and
late phase (Fig. 3) [41, 42]. The filling may be complete
or partial depending on lesion size and/or the presence
of mixoid or fibrotic degeneration [43]. Hepatic fat de-
position/sparing is defined as nonmasslike, nonspherical,
hyper/hypoechoic area of parenchyma in a characteristic
location for fat deposition/sparing. Characteristic areas
include liver parenchyma nearby the gallbladder and an-
terior to the right portal vein in segment 4. Hepatic fat
deposition/sparing shows isoenhancement to the liver in
all phases [44–46]. If the hyper/hypoechoic area is not in
a characteristic location for fat deposition/sparing,
categorize as CEUS LR-2 (see below) (Fig. 4). In case of
detection of isoenhancing nodule at CEUS, observation
should undergo CEUS LR-2 classification if solid nodule
< 10mm (Fig. 5), whereas if isoenhancing nodule is ≥ 10
mm, it should be categorized as CEUS LR-3 (see below).
On the other hand, LR-3 nodules with interval size sta-
bility for more than 2 years can return to LR-2. These
small nodules are probably typical regenerative or low-
grade dysplastic nodules [47]. Any isoenhancing observa-
tion of any size, nonmasslike and without typical
appearance of hepatic fat deposition or fat sparing,
should be also categorized as LR-2 (Fig. 6).
Noteworthy, the CEUS enhancement features for
HCC, hepatocellular adenoma (HCA,) and focal nodular
hyperplasia (FNH) may overlap [47–54]. Hence, on a
precautionary basis, in the clinical setting of patients at
risk for HCC, nodules with CEUS feature of FNH and
HCA should not be categorized as CEUS LI-RADS 1 or
CEUS LI-RADS 2.
Any nodule not showing any APHE nor washout must
be categorized as CEUS LR-3 regardless of size (Fig. 7).
A nodule smaller than 2 cm, without any APHE but
showing late and mild washout, should be also assigned
to CEUS LR-3 category. On the other hand, any nodule
larger than 2 cm, without any APHE but showing late
and mild washout, must be assigned to CEUS LR-4
category.
Nodules showing APHE (not rim or peripheral
globular) without washout of any type should be cate-
gorized, depending on size, as CEUS LR-3 (when the
nodule is smaller than 10 mm) or CEUS LR-4 (≥ 10
mm) respectively (Fig. 8). At the same time, nodules
showing APHE (not rim or peripheral globular) but
presenting with late and mild washout should be cat-
egorized, depending on size, as CEUS LR-4 (when the
Fig. 7 CEUS LI-RADS 3 (intermediate malignancy probability). Nodule in a 74-year-old man with virus B-related cirrhosis. Baseline US image (a)
shows a slightly hypoechoic lesion sized 3 cm in the segment IV (arrow). At CEUS, the nodule appears moderately hypoechoic during the arterial
phase (b) and isoechoic to the adjacent liver parenchyma in the extended portal venous (c) phase (arrows)
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Fig. 8 CEUS LI-RADS 4 (probably HCC). Nodule in a 52-year-old woman with virus C-related cirrhosis. Baseline US image (a) shows a slightly
hypoechoic lesion sized 1.5 cm in the segment VIII (calipers). No vascular signal is detectable at color-Doppler (b) (arrow). At CEUS, the nodule is
highly hypervascular during the arterial phase (c) (arrow) and isoechoic in the extended portal venous phase (d) (arrow)
Fig. 9 CEUS LI-RADS 5 (definitely HCC). Nodule in a 72-year-old man with virus B-related cirrhosis. Baseline US image (a) shows two moderately hypoechoic
lesions sized, respectively, 2.2 cm and 0.7 cm in the segment V (calipers). At CEUS, the largest one is markedly hypervascular during the arterial phase (b) (arrows),
becoming isoechoic 45 s after contrast medium injection (c) (arrow) and showing moderate wash-out 120 s after contrast medium injection (d) (arrows)
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Fig. 10 CEUS LI-RADS M (probably or definitely malignant but not HCC specific) nodule. Cholangiocarcinoma in a 87-year-old man with virus B-
related cirrhosis. Baseline US image shows a markedly heterogeneous lesion sized 8.5 cm in the segment VI (a) (arrows). No vascular signal is
detectable at color-Doppler (b). At CEUS (c), the nodule shows rim enhancement surrounding a constantly avascular area (arrows)
Fig. 11 CEUS LI-RADS M (probably or definitely malignant but not HCC specific) nodule. Metastasis in a 32-year-old woman with virus B-related
cirrhosis. Baseline US image (a) shows a hypoechoic lesion with not well-defined margins sized 5 cm in the segment IV (calipers). At CEUS, the
lesion is heterogeneously vascularized during the arterial phase (b) (arrow) showing early wash-out: 34 s after contrast medium injection
(c) (arrow)
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nodule is smaller than 10 mm) or CEUS LR-5 (≥ 10
mm) respectively (Fig. 9).
In LR-M category, any nodule of any size should be
included, which may show any of the following criteria
[55–60]:
1. Rim APHE: “ring-like” APHE in which
enhancement is most evident at the periphery of
the nodule (Fig. 10);
2. Early (< 60 s) washout: temporally defined subtype
of washout in which onset is within 60 s from
contrast injection. Usually marked in degree
(Fig. 11);
3. Marked washout.
At CEUS, the vast majority of malignant nodules typ-
ically show washout, including liver metastases, intrahe-
patic cholangiocarcinoma (ICC), and other tumors with
Fig. 12 CEUS LI-RADS TIV (tumor in vein). Neoplastic thrombosis in a 84-year-old man with virus B-related cirrhosis. Baseline US image shows (a)
multiple thrombi in the lumen of portal vein (arrows). At CEUS, marked enhancement is evident in their context during the early arterial phase
(b) (arrows), followed by a clear-cut wash-out in the extended portal venous phase (c) (arrows)
Fig. 13 Non-neoplastic thrombosis in a 62-year-old man with virus B-related cirrhosis. At CEUS, no enhancement is appreciable in the context of
the right branch of portal vein during the arterial (a), portal venous (b), and late (c) phases, respectively (arrows)
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fibrotic component which may show delayed central en-
hancement on CT or MRI [61–65]. Hence, to maintain
specificity for HCC, CEUS characterization of washout
requires assessment of its “onset” and “degree,” not just
its presence. As consequence, observations with late and
mild washout may be categorized as CEUS LR-3, LR-4,
or LR-5. Nodules with early or marked washout should
be categorized LR-M. ICC may be typically included in
this category in a cirrhotic liver.
Finally CEUS LR-TIV (definite tumor in vein) includes
observation of enhancing tissue within a vein, independ-
ently from the detection of a coexisting liver tumor. Tu-
moral invasion of veins must be differentiated from
bland thrombus [66]. To this purpose, the arrival time of
microbubble contrast agent to the vein helps to distin-
guish tumor in vein from bland thrombus [67]:
– Early arrival time (~ same time as contrast
enhancement of hepatic artery): favors tumor in vein
(Fig. 12).
– Arrival time of several seconds (~ 10) after contrast
enhancement of hepatic artery: favors portal flow in
patent portion of non-occlusive/recanalized bland
thrombus.
Bland thrombus shows lack of vascularization (Fig. 13).
The proximity with any liver mass may help in etiology
definition. In particular, if TIV is contiguous or associ-
ated with any LI-RADS 4 or 5 lesions, tumor in vein is
probably or definitely attributable to HCC, whereas if
TIV is near LR-M, it is probably due to non-HCC malig-
nancy. If no masses are detected, etiology is
undetermined.
HCC and CEUS LI-RADS: final considerations
CEUS is currently recommended as an adjunct tool in
the imaging work-up of HCC, either in the LI-RADS
lexicon or in other international guidelines, with encour-
aging results also in terms of cost-benefit analysis [24,
68, 69]. Of note, there is still lack of consensus among
different Scientific Societies regarding the precise role of
CEUS in the diagnostic algorithm for the
characterization of HCC. On one hand, various scientific
societies, including ACR and Japanese, Italian, German,
and British, suggest the use of CEUS in the diagnostic al-
gorithm of HCC in their guidelines (www.webaisf.org,
www.drg.de, and www.nice.org.uk, respectively). In the
latest version of European Association for Study of Liver
(EASL) guidelines on the management of HCC, CEUS is
also considered a diagnostic tool for HCC as well as CT
and MRI [68]. On the other hand, other Korean and
American Societies, such as the Korean Liver Cancer
Study Group, the American Association for the Study of
Liver Diseases, and the Organ Procurement and
Transplantation Network, suggest the use of CT and
MR only [68, 69]. Further refinement may allow a desir-
able and better uniformity in international guidelines.
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